Palliative management of Parkinson disease: Focus on nonmotor, distressing symptoms

Journal of Pharmacy Practice

Volumn 21, Issue 4, 2008, Pages 262-272

  Chen, Jack J ^a   Trombetta, Dominick P ^b   Fernandez, Hubert H ^c  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WILKES UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Dementia; Depression; Palliative; Parkinson disease; Psychosis

Indexed keywords

AMANTADINE; ATROPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BOTULINUM TOXIN; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENEMA; FLUPHENAZINE; HALOPERIDOL; LAXATIVE; MEMANTINE; METOCLOPRAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; ONDANSETRON; QUETIAPINE; RISPERIDONE; ROTIGOTINE; SELEGILINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; TRIMETHOBENZAMIDE; UNINDEXED DRUG;

AGITATION; AGRANULOCYTOSIS; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DYSPHAGIA; EPIDEMIOLOGICAL DATA; FECES IMPACTION; GASTROINTESTINAL SYMPTOM; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HOSPICE CARE; HOSPITAL ADMISSION; HUMAN; HYPERSALIVATION; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROPROTECTION; ON OFF PHENOMENON; ORTHOSTATIC HYPOTENSION; PAIN; PALLIATIVE THERAPY; PARKINSON DISEASE; PARKINSONISM; PATIENT CARE; PERISTALSIS; PHYSIOTHERAPY; PSYCHOLOGICAL WELL BEING; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; TERMINAL CARE; VOMITING;

EID: 47649110820     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008318370     Document Type: Review

References (59)

1. Biglan KM, Schwid S., Eberly S., et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006 ; 21: 616-623.
2. Noyes K., Dick AW, Holloway RG Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health. 2006 ; 9: 28-38.
3. Reichmann H., Boas J., Macmahon D., Myllyla V., Hakala A., Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005 ; 111: 21-28.
4. Lees AJ, Katzenschlager R., Head J., Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001 ; 57: 1687-1694.
5. D'Amelio M., Ragonese P., Morgante L., et al. Long-term survival of Parkinson disease: a population-based study. J Neurol. 2006 ; 253: 33-37.
6. Orsini L., Kennedy S., Castelli-Haley J., Huse D. Healthcare utilization and expenditures among Medicaid patients with Parkinson's disease. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research ; May 16-19, 2004 ; Arlington, VA.
7. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc. 2002 ; 77: 918-925.
8. Lapane KL, Fernandez HH, Friedman JH Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson disease in residents in long-term care facilities. Pharmacotherapy. 1999 ; 19: 1321-1327.
9. Fernandez HH, Lapane KL Predictors of mortality among nursing home residents with a diagnosis of Parkinson disease. Med Sci Monit. 2002 ; 8: CR241 - CR246.
10. National Consensus Project for Quality Palliative Care. Clinical practice guidelines for quality palliative care, 2004. Available at: http://www.nationalconsensusproject.org/Guidelines_Download.asp. Accessed October 2, 2006.
11. Marras C., Tanner CM Epidemiology of Parkinson disease. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles & Practice. 2 nd ed. New York, NY: McGraw-Hill ; 2004: 177-195.
12. US interim projections by age, sex, race, and Hispanic origin. Washington, DC: US Census Bureau, 2004. Available at: http://www.census.gov/ipc/ www./usinterimproj. Accessed October 2, 2006.
13. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 ; 157: 1015-1022.
14. Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson disease. J Am Geriatr Soc. 1996 ; 44: 394-399.
15. Buchanan RJ, Wang S., Huang C., Simpson P., Manyam BV Analyses of nursing home residents with Parkinson disease using the minimum data set. Parkinsonism Relat Disord. 2002 ; 8: 369-380.
16. Billings JA What is palliative care ? J Palliat Med. 1998 ; 1: 73-81.
17. Center to Advance Palliative Care. Available at: http://www.capc.org. Accessed May 20, 2008.
18. American Academy of Hospice and Palliative Medicine. Available at: http://aahpm.org. Accessed May 20, 2008.
19. Teno JM, Clarridge BR, Casey V., et al. Family perspectives on end-of-life care at the last place of care. JAMA. 2004 ; 291: 88-93.
20. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA Tegaserod (Zelnorm) for the treatment of constipation in Parkinson disease. Mov Disord. 2006 ; 21: 115-116.
21. Ondo WG, Hunter C., Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson disease. Neurology. 2004 ; 62: 37-40.
22. Janvin CC, Larsen JP, Salmon DP, Galasko D., Hugdahl K., Aarsland D. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord. 2006 ; 21: 337-342.
23. Fernandez HH, Crucian GP, Seignourel P., et al. Laterality, location, type and severity of motor dysfunction may predict cognitive decline in Parkinson's disease [abstract]. Mov Disord. 2005 ; 20: 1243-1244.
24. McKeith IG Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. J Alzheimers Dis. 2006 ; 9 (suppl 3). 417-423.
25. Aarsland D., Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity ? J Geriatr Psychiatry Neurol. 2004 ; 17: 137-145.
26. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson disease with dementia and dementia with lewy bodies. Int J Geriatr Psychiatry. 2005 ; 20: 938-944.
27. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson disease. N Engl J Med. 2004 ; 351: 2509-2518.
28. Edwards KR, Hershey L., Wray L., et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord. 2004 ; 17 (suppl 1). 40-48.
29. Aarsland D., Laake K., Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002 ; 72: 708-712.
30. Ravina B., Putt M., Siderowf A., et al. Donepezil for dementia in Parkinson's disease: a randomized, double-blind, placebo-controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005 ; 76: 934-939.
31. Cummings JL Depression and Parkinson's disease. A review. Am J Psychiatry. 1992 ; 149: 443-454.
32. Jones RN, Marcantonio ER, Rabinowitz T. Prevalence and correlates of recognized depression in U.S. nursing homes. J Am Geriatr Soc. 2003 ; 51: 1404-1409.
33. Chen JJ Anxiety, depression, and psychosis in Parkinson disease: unmet needs and treatment challenges. Neurol Clin. 2004 ; 22 (suppl 3). S63 - S90.
34. Starkstein SE, Mayberg HS, Leiguarda R., Preziosi TJ, Robinson RG A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson disease. J Neurol Neurosurg Psychiatry. 1992 ; 55: 377-382.
35. Starkstein SE, Preziosi TJ, Robinson RG Sleep disorders, pain, and depression in Parkinson disease. Eur Neurol. 1991 ; 31: 352-355.
36. Fenelon G., Mahieux F., Huon R., Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000 ; 123 (pt 4). 733-745.
37. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson disease: drug-induced psychiatric states. Adv Neurol. 1995 ; 65: 115-138.
38. de Smet Y., Ruberg M., Serdaru M., Dubois B., Lhermitte F., Agid Y. Confusion, dementia, and anticholinergics in Parkinson disease. J Neurol Neurosurg Psychiatry. 1982 ; 45: 1161-1164.
39. Miyasaki JM, Shannon K., Voon V., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 ; 66: 996-1002.
40. Reading PJ, Luce AK, McKeith IG Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001 ; 16: 1171-1174.
41. Bergman J., Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002 ; 25: 107-110.
42. Pathak A., Senard JM Pharmacology of orthostatic hypotension in Parkinson disease: from pathophysiology to management. Expert Rev Cardiovasc Ther. 2004 ; 2: 393-403.
43. Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004 ; 10: 129-136.
44. Ford B. Pain in Parkinson disease. Clin Neurosci. 1998 ; 5: 63-72.
45. Sage JI Pain in Parkinson disease. Curr Treat Options Neurol. 2004 ; 6: 191-200.
46. Ferrell BA The management of pain in long-term care. Clin J Pain. 2004 ; 20: 240-243.
47. American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002 ; 50 (suppl 6). S205 - S224.
48. Morrison RS, Magaziner J., Gilbert M., et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci. 2003 ; 58: 76-81.
49. Factor SA, Brown DL, Molho ES Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord. 2000 ; 15: 167-169.
50. Pahwa R., Lyons KE Options in the treatment of motor fluctuations and dyskinesias in Parkinson disease: a brief review. Neurol Clin. 2004 ; 22 (suppl 3). S35 - S52.
51. Sage JI, Mark MH Basic mechanisms of motor fluctuations. Neurology. 1994 ; 44 (suppl 6). S10 - S14.
52. Chapuis S., Ouchchane L., Metz O., Gerbaud L., Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005 ; 20 (2). 224-230.
53. Schrag A., Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000 ; 123 (pt 11). 2297-2305.
54. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res. 2000 ; 9: 87-100.
55. Schrag A., Jahanshahi M., Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord. 2000 ; 15: 1112-1118.
56. Dewey RB Jr. Management of motor complications in Parkinson disease. Neurology. 2004 ; 62 (6 suppl 4). S3 - S7.
57. Olanow CW Present and future directions in the management of motor complications in patients with advanced PD. Neurology. 2003 ; 61 (suppl 3). S24 - S33.
58. Center for Gerontology and Healthcare Research. Brown Medical School. Available at: http://www.chcr.brown.edu/pcoc/toolkit.htm. Accessed May 20, 2008.
59. Ellershaw J., Ward C. Care of the dying patient: the last hours or days of life. BMJ. 2003 ; 326: 30-34.